Pharma Journalist -

Iterum Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with…
Read More...

The 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Summit) this December will be your foremost drug development focused gene editing meeting, providing you with the…
Read More...

AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier…
Read More...

Astellas Pharma Inc. announced the company's decision to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal…
Read More...

Genome editing represents one of the most significant recent advancements in molecular biology. CRISPR/Cas9 has been seen by many as cutting-edge (if you can pardon the pun) for its…
Read More...

TreeFrog Therapeutics has announced a research collaboration with the University of Pittsburgh focused on the potential of tertiary lymphoid structures (TLS) in immuno-oncology, an…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) approved the indication extension for DARZALEX (daratumumab) subcutaneous…
Read More...

Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous…
Read More...

Be Biopharma, Inc. announced key milestones alongside a new round of funding as its lead program, BE-101 for Hemophilia B, enters the clinic, and its second development candidate for…
Read More...